Patents Examined by Sudhakar Katakam
  • Patent number: 10280133
    Abstract: The present invention relates to a process for the preparation of 4-aminobenzoamidine (4-AMBA) salts of general formula (I) preferably the salts thereof with hydrochloric or hydrobromic acid, particularly preferred the dichloride salt.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: May 7, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Weitong Dong, Christian Wolfgang Hemp, Xiangle Jin, Jun Lu, Ulrich Scholz, Shengmin Su, Wei Xu, Jinsong Yang
  • Patent number: 10278969
    Abstract: The present invention relates to solid pharmaceutical dosage forms comprising the drug substance 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea or any pharmaceutically acceptable salt thereof. It further relates to processes of making said solid pharmaceutical dosage forms.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: May 7, 2019
    Assignee: Novartis AG
    Inventor: Suzie Ribeiro
  • Patent number: 10278966
    Abstract: A method of isolating at least one phenanthroindolizidine alkaloid, in particular with telomerase inhibitory activity, from Tylophora atrofolliculata is used to isolate and obtain for example about six to eight phenanthroindolizidine alkaloids, including at least four new phenanthroindolizidine alkaloids which have not been previously isolated. Experimental tests confirmed an exceptional telomerase inhibitory activity of the phenanthroindolizidine alkaloids isolated. A pharmaceutical composition includes at least one phenanthroindolizidine alkaloid and at least one pharmaceutical tolerable excipient. Still further, a method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid isolated from Tylophora atrofolliculata. Also, a method of treating a subject suffering from cancer includes administering to the subject at least one phenanthroindolizidine alkaloid having certain formula.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: May 7, 2019
    Assignee: Macau University of Science and Technology
    Inventors: Zhi-Hong Jiang, Jing-Rong Wang, Cheng-Yu Chen, Guo-Yuan Zhu
  • Patent number: 10272056
    Abstract: The present application relates to methods of treating a subject with a disease or disorder associated with a mitochondrial deficit, comprising: determining at least one of a type or degree of the mitochondrial deficit in the subject; and administering an amount of a butyrate compound to the subject based at least partially on the determining step so as to promote Adenosine triphosphate (ATP) production in the subject as well as to methods of screening for compounds that restore cellular mitochondrial activity.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: April 30, 2019
    Assignee: The George Washington University, A Congressionally Chartered Not-for-Profit Corporation
    Inventors: Anne Chiaramello, Martine Uittenbogaard
  • Patent number: 10265322
    Abstract: The present invention relates to the use of PAR1 antagonists, in particular of vorapaxar, of atopaxar and of 3-(2-chlorophenyl)-1-[4-(4-fluorobenzyl)piperazin-1-yl]propenone, or a pharmaceutically acceptable salt thereof, for preventing and/or treating pelvi-perineal functional pathological conditions, and more particularly painful bladder syndrome.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: April 23, 2019
    Assignee: Pierre Fabre Medicament
    Inventors: Bruno Le Grand, Didier Junquero, Nicolas Monjotin
  • Patent number: 10265408
    Abstract: The present disclosure relates to novel cleavable conjugates of antibiotics and an antibacterial cell-penetrating peptide, and methods to make and use the novel cleavable conjugates of antibiotics and an antibacterial cell-penetrating peptide.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: April 23, 2019
    Assignee: Purdue Research Foundation
    Inventors: Jean Anne Chmielewski, Mohamed Seleem
  • Patent number: 10260006
    Abstract: A unique process and catalyst is described that operates efficiently for the direct production of a high cetane diesel type fuel or diesel type blending stock from stochiometric mixtures of hydrogen and carbon monoxide. This invention allows for, but is not limited to, the economical and efficient production high quality diesel type fuels from small or distributed fuel production plants that have an annual production capacity of less than 10,000 barrels of product per day, by eliminating traditional wax upgrading processes. This catalytic process is ideal for distributed diesel fuel production plants such as gas to liquids production and other applications that require optimized economics based on supporting distributed feedstock resources.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: April 16, 2019
    Assignee: Greyrock Technology LLC
    Inventors: Robert Schuetzle, Dennis Schuetzle
  • Patent number: 10251894
    Abstract: The present invention relates to methods of preventing, inhibiting, delaying, and/or mitigating seizures by administration of a steroid, e.g., a neurosteroid, e.g., allopregnanolone.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: April 9, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Michael A. Rogawski, Dorota Zolkowska
  • Patent number: 10251850
    Abstract: The present invention provides process for preparation of cysteamine bitartrate comprising reacting cysteamine or its salt with tartaric acid. The present invention further provides crystalline form L1 of cysteamine bitartrate having characteristic diffraction peaks at 10.36, 14.54, 17.23, 18.03, 19.24, 20.76, 21.20, 22.02, 23.37, 23.64, 27.71, 28.28, 29.26, 31.33, 32.84, 33.83, 35.51, 36.74±0.2 degree two theta in an X-ray diffraction pattern and process for preparation thereof. The present invention provides crystalline form L2 of cysteamine bitartrate having characteristic diffraction peaks at 7.4, 10.3, 11.0, 11.4, 14.4, 14.9, 18.6, 19.4, 20.1, 20.8, 21.9, 22.3, 22.5, 23.5±0.2 degree two theta in an X-ray diffraction pattern and process for preparation thereof.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: April 9, 2019
    Assignee: LUPIN LIMITED
    Inventors: Pankaj Ramchandra Chaudhari, Sukhdeo Sampat Gunjal, Raju Muktaji Walunj, Anurag Trivedi, Rajinder Singh Siyan, Nandu Baban Bhise, Girij Pal Singh
  • Patent number: 10252986
    Abstract: The present invention provides an improved process for the preparation of exametazime, which is used as ligand in preparation of technetium-99m complex.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: April 9, 2019
    Assignee: JUBILANT GENERICS LIMITED
    Inventors: Sujay Biswas, Vikas Bansal, Rohit Chakravarty, Mokkapati Umamaheshwar Prasad, Mukesh Masand, Dharam Vir
  • Patent number: 10246406
    Abstract: ?-Substituted ?-amino acids, ?-substituted ?-amino acid derivatives, and ?-substituted ?-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The ?-substituted ?-amino acid derivatives and ?-substituted ?-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: April 2, 2019
    Assignee: QUADRIGA BIOSCIENCES, INC.
    Inventors: Bernd Jandeleit, Wolf-Nicolas Fischer, Kerry J. Koller, Gordon Ringold
  • Patent number: 10245326
    Abstract: A compound is provided that has the formula (II): where R1 in each occurrence is independently H, or C1-C4 alkyl; R2 is a nullity or CH—CH3, R3 is a nullity or C(O)—R6—NH; R6 is C2-C6 alkyl, (CH2CH2—O)n, or (CH(OH)CH2)n; n is an integer of between 1 and 4; R4 is a nullity or NH—R6—C(O); and R5 is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine, blood brain barrier (BBB) peptide, membrane translocating peptide, TAT peptides, endocannabinoids 1 & 2, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, thyrotropin, an angiotensin, galanin, neuropeptide Y, thyrotropin-releasing hormone, gonadotropnin-releasing hormone, growth hormone-releasing hormone, luteinizing hormone, vasoactive intestinal peptide transferrin, glucosyl ester, lactic acid, leucine, tryptophan, glutamic acid.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: April 2, 2019
    Inventor: Landon C. G. Miller
  • Patent number: 10245273
    Abstract: Pharmaceutical products comprising a hypolipidemic agent and a testosterone ester such as testosterone undecanoate are provided. Methods of safely treating a testosterone deficiency or its symptoms with the inventive pharmaceutical products are also provided.
    Type: Grant
    Filed: December 24, 2014
    Date of Patent: April 2, 2019
    Assignee: Clarus Therapeutics, Inc.
    Inventors: Wael Salameh, Panayiotis Constantinides
  • Patent number: 10239848
    Abstract: Compositions that include certain phenyl substituted cyclohexenyl compounds are administered to a subject in a method for treating obesity or an associated disease or disorder or in a method of reducing food consumption or body weight.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: March 26, 2019
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Ruth Gallily, Raphael Mechoulam, Aviva Breuer
  • Patent number: 10231969
    Abstract: This invention directed to methods for treating select RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders using CDK4/6 inhibitors in specific dosing and combination or alternation regimes. In one aspect, treatments of select RB-positive cancers are disclosed using specific CDK4/6 inhibitors in combination or alternation with another chemotherapeutic, for example, an additional kinase inhibitor, PD-1 inhibitor, or BCL-2 inhibitor, or combination thereof.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: March 19, 2019
    Assignee: GI Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John E. Bisi, Patrick Joseph Roberts, Jessica A. Sorrentino, Hannah S. White
  • Patent number: 10231924
    Abstract: A compounded topical composition may include an antiviral component, a topical base component, and a local anesthetic component. The antiviral component may include fine powder obtained by grinding oral tablets of one or more antiviral actives. The topical component may include the local anesthetic component. The local anesthetic component may be present in an amount between about 2% and about 8% by weight of the compounded topical composition and the antiviral component may be present in an amount between 4% and 12% by weight of the compounded topical composition. The antiviral component may include acyclovir, valaciclovir, penciclovir, famciclovir, or combinations thereof, and the topical base component may be a lidocaine topical, a lidocaine and prilocaine topical, or both.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: March 19, 2019
    Assignee: CMPD LICENSING, LLC
    Inventor: Jay Richard Ray, II
  • Patent number: 10226443
    Abstract: Methods, agents and compositions thereof for treating psoriatic arthritis (PsA) are encompassed herein.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: March 12, 2019
    Assignees: New York University, Memorial Sloan-Kettering Cancer Center, Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana (Fisabio)
    Inventors: Jose U. Scher, Carles Ubeda, Dan R. Littman, Eric G. Pamer, Steven B. Abramson, Sergei B. Koralov
  • Patent number: 10227295
    Abstract: Disclosed are selective histone deactylase inhibitors (HDACi) that having Formula I. Methods of making and using these inhibitors for the treatment of cancer, in particular melanoma are also disclosed.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: March 12, 2019
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Board of Trustees of The University of Illinois
    Inventors: Eduardo M. Sotomayor, Joel A. Bergman, Alan P. Kozikowski, Alejandro V. Villagra, Karrune V. Woan
  • Patent number: 10221132
    Abstract: The present invention relates to a process for the synthesis of cysteamine or a salt thereof.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: March 5, 2019
    Assignee: CHEMELECTIVA SRL
    Inventors: Marco Baratella, Mauro Gaboardi, Graziano Castaldi, Erminio Oldani
  • Patent number: 10208075
    Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: February 19, 2019
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Ryan Kelley, Hui Li, Thilo Heckrodt, Yan Chen, Darren McMurtrie, Kin Tso, Vanessa Taylor, Rajinder Singh, Rose Yen, Jack Maung